SCHEMBL6344984

SCHEMBL6344984

Oc1ccnc2c1cnn2-c1ccccn1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 3/20 0.55
GSK3B P49841 1/20 0.44
DPP4 P27487 1/20 0.43
SLC2A1 P11166 2/20 0.43
SLC2A2 P11168 2/20 0.43
SLC2A3 P11169 2/20 0.43
SPR P35270 4/20 0.42
CYP1A2 P05177 2/20 0.41
MAPK14 Q16539 1/20 0.41
HPGD P15428 4/20 0.39
ALDH1A1 P00352 3/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
HSD17B10 Q99714 2/20 0.37
ALOX15 P16050 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALKBH2 Q6NS38 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071403 0.80 GSK3B (0.52) CYP17A1GSK3BDPP4SLC2A1SLC2A2
SCHEMBL11062025 0.75 CYP17A1 (0.50) CYP17A1GSK3BDPP4CYP1A2MAPK14
SCHEMBL1269006 0.74 CYP17A1 (0.49) CYP17A1GSK3BDPP4SPRCYP1A2
SCHEMBL840321 0.74 GSK3B (0.52) CYP17A1GSK3BDPP4SLC2A1SLC2A2
SCHEMBL3876328 0.74 KDM4E (0.66) CYP17A1GSK3BSLC2A1SLC2A2SLC2A3
SCHEMBL29714856 0.73 KDM4E (0.67) CYP17A1GSK3BDPP4SLC2A1SLC2A2
SCHEMBL5683198 0.73 KDM4E (0.67) CYP17A1GSK3BDPP4SLC2A1SLC2A2
SCHEMBL15105514 0.73 CYP17A1 (0.73) CYP17A1CYP1A2
SCHEMBL10187548 0.72 CYP17A1 (1.00) CYP17A1GSK3BCYP1A2ALDH1A1HSD17B10
SCHEMBL32668647 0.72 MAPT (0.52) CYP17A1GSK3BDPP4SLC2A1SLC2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949648-B2 Condensed pyrazole derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-09-27 US disclosed
US-20030187014-A1 Condensed pyrazole derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
EP-1270572-A1 CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187014-A1 Condensed pyrazole derivatives, process for producing the same and use thereof PTGS1, PTGIS, IL5 CYP17A1 477/4885GSK3B 3332/4885DPP4 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.